Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
OraSure announced FDA clearance of its Colli-Pee™ Dx Urine Collection Kit for use with Roche molecular diagnostic systems to detect four sexually transmitted infections. This is a material regulatory milestone that expands the company's product portfolio and market reach through a partnership with a major diagnostics company (Roche), but does not fit neatly into the more specific event categories (not an earnings release, M&A activity, impairment, or litigation). The disclosure warrants classification as a material product/regulatory event under "other_material."
View raw filing on EDGAR →
8-K
M&A activity
confidence 72%
filed 2026-06-11
Item 1.01
Prairie Operating Co. entered into two material definitive agreements on June 10, 2026: a Second Amendment to its credit facility reaffirming a $475 million borrowing base with modified covenants and redetermination procedures, and a Letter Agreement with Hudson Bay PH XIX LLC permitting conversion of Series F Preferred Stock into up to 21.2 million additional common shares with adjusted warrant issuance percentages. These agreements represent material changes to the company's capital structure, financial obligations, and shareholder dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-11
Item 8.01
The filing discloses a private offering of Exchangeable Senior Notes due 2031 priced at 3.50%, issued to qualified institutional buyers under Rule 144A. Exchangeable notes are convertible into the company's common stock, making this a dilutive issuance. The pricing announcement on June 11, 2026 represents a material capital-raising event that would affect investor assessment of share dilution and the company's financing strategy.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-11
Item 2.01
KalVista Pharmaceuticals completed a merger with a Parent entity on June 11, 2026, resulting in a change of control. The transaction included a tender offer and modification of convertible note terms to provide cash conversion rights at $27.00 per share, with the Parent acquiring control of the Company effective at the Effective Time.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-11
Item 3.01
Following completion of the merger, KalVista notified Nasdaq on June 10–11, 2026 of the consummation and requested delisting of its shares from The Nasdaq Global Market. Trading was halted effective June 10, 2026 and ceased on June 11, 2026, with the Company intending to file Form 25 and Form 15 to remove listing and terminate SEC registration.
View raw filing on EDGAR →
8-K
Exec departure
confidence 65%
filed 2026-06-11
Item 5.02
Eight directors (Brian J. G. Pereira, Benjamin L. Palleiko, William Fairey, Laurence Reid, Bethany Sensenig, Nancy Stuart, Patrick Treanor, and Edward W. Unkart) resigned from the Company's board and all committees effective immediately in connection with the merger consummation, with no disagreement cited.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-11
Item 2.03
The filing discloses creation of a direct financial obligation under Item 2.03, incorporating Item 1.01 by reference; the specific nature of the obligation (debt, lease, contingent liability, or other commitment) cannot be determined without access to the referenced Item 1.01 content.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-11
Item 3.03
Item 3.03 discloses a material modification to rights of security holders, incorporating by reference Items 3.01, 5.01, and 5.03; the specific nature of the modification cannot be reliably determined from the cross-references alone, though it likely relates to the merger, delisting, or change of control.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 93%
filed 2026-06-11
Item 5.02
Ms. Jehna Silva was appointed as a director of Farmers & Merchants Bancorp effective June 8, 2026, and assigned to three board committees (CRA, Budget and Finance, and ALCO). The appointment is material due to its impact on board composition and governance structure, and notably involves a family relationship with CEO Kent Steinwert that is relevant to investors assessing board independence.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-06-11
Item 4.01
Item 4.01 discloses the dismissal of Beckles & Co., Inc. as independent registered public accounting firm on June 8, 2026, and the appointment of Dylan Floyd Accounting & Consulting as the new auditor on June 10, 2026. This is a classic auditor change event. The filing explicitly states no disagreements existed between the registrant and the dismissed auditor, and no prior consultations occurred with the new auditor, indicating a routine transition rather than a dispute-driven change.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-11
Item 2.02
Item 2.02 discloses the issuance of a press release on June 11, 2026 regarding results of operations and financial condition. This is a standard earnings release disclosure, typically material to investors as it communicates the registrant's financial performance and results.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-11
Item 1.01
Edesa Biotech entered into a Securities Purchase Agreement on June 10, 2026, for a private placement of 729,241 common shares at $4.69–$5.21 per share, raising approximately $3.5 million. This unregistered equity issuance materially dilutes existing shareholders' ownership and increases the company's share count.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Compass Therapeutics' Annual Meeting of Stockholders held on June 10, 2026. The filing presents voting results for four proposals: election of two Class III directors (Schuetz and Lindahl), ratification of CohnReznick LLP as independent auditor, advisory vote on named executive officer compensation, and advisory vote frequency on compensation. The detailed vote tallies (For/Against/Withheld/Broker Non-votes) for each proposal are the core content of this 8-K section.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-11
Item 1.01
VSee Health entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. on June 2, 2026, granting the investor the right to purchase up to $10 million of common stock over three years at 97% of the lowest daily VWAP, with an Exchange Cap of approximately 19.99% of outstanding shares and immediate issuance of 532,481 commitment shares. The unregistered private placement relies on Section 4(a)(2) exemption and materially dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 80%
filed 2026-06-11
Item 3.02
VSee Health entered into a securities purchase agreement on June 8, 2026, issuing a secured promissory note for $271,739.13 principal at 18% annual interest due December 8, 2026, in an unregistered transaction exempt under Section 4(a)(2) of the Securities Act and/or Regulation D. The transaction represents a material financing arrangement with a security interest in company assets and mandatory repayment upon equity financing receipt, indicating significant financial stress.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
Item 5.07
Shoe Carnival Inc held its 2026 Annual Meeting of Shareholders on June 10, 2026, with shareholder approval of director elections (Diane E. Randolph and J. Wayne Weaver), an advisory compensation vote, auditor ratification (Deloitte & Touche LLP), and a material amendment to change the company's legal name to Shoe Station Group, Inc., effective June 12, 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-11
Item 7.01
Dana announced a proposed combination with Eaton Corporation's Vehicle and eMobility business segments, with Dana to merge with a SpinCo entity created from Eaton's separation. This constitutes entry into a material acquisition/merger transaction. The disclosure explicitly references the "Proposed Combination" and describes the transaction structure involving exchange offers and merger, which are hallmark M&A activities requiring 8-K disclosure under Item 1.01 or 2.01, though filed here under Item 7.01 (Regulation FD Disclosure).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Orthofix Medical Inc. held its Annual Meeting of Shareholders on June 10, 2026, with voting results disclosed on four matters: election of ten directors, advisory approval of executive compensation, ratification of Ernst & Young LLP as auditor, and approval of Amendment No. 5 to the Second Amended and Restated Stock Purchase Plan increasing available shares by 1,250,000.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
Item 5.07
This Item 5.07 disclosure reports the results of the Annual Meeting of Stockholders held on June 10, 2026, including voting outcomes for two proposals: election of two Class II directors (Rainer Erdtmann and Eric Aguiar) and ratification of Deloitte & Touche LLP as independent auditor. The filing provides detailed vote counts (for, against, abstentions, and broker non-votes) for each proposal, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
This disclosure announces initial Phase 1b clinical trial data for budoprutug in primary ITP, showing favorable safety and efficacy signals (90% B-cell depletion, platelet responses in 4/6 patients at 250 mg dose, no serious adverse events). While clinical trial progress is material to a biotech company's valuation and investor assessment, it does not fit neatly into the standard 8-K event taxonomy (not an earnings release, M&A activity, restatement, or other defined categories). The data supports continued development and is clearly significant to investors, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-11
Item 8.01
Silence Therapeutics disclosed Phase 1 clinical trial data for divesiran (SANRECO study) presented at the EHA 2026 Annual Congress. While this is a clinical development update rather than a traditional earnings release or defined material event, the presentation of follow-up and quality-of-life data from a first-in-class siRNA therapy in a rare disease indication (polycythemia vera) would be material to investors evaluating the company's pipeline and clinical progress. The disclosure does not fit neatly into earnings_release, material_litigation, or other specific categories, making other_material the most appropriate classification.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-11
Item 1.01
Atossa Therapeutics entered into a securities purchase agreement on June 10, 2026, for a registered direct offering of 1,363,638 shares of common stock and Series A and B warrants at $3.30 per share, expected to raise approximately $4.1 million in net proceeds. While technically registered (via Form S-3), this is a direct offering to institutional investors with significant warrant dilution (up to 2.7 million additional shares if warrants are exercised), representing material equity dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-06-11
Item 8.01
Enliven Therapeutics announced updated positive Phase 1 clinical trial data from the ENABLE trial evaluating ELVN-001 in patients with chronic myeloid leukemia, including key outcomes from an FDA End-of-Phase 1 meeting and selection of the 80 mg QD dose for Phase 3 development. This represents material clinical progress for the company's lead candidate that affects investor assessment of the pipeline and regulatory pathway.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-11
Item 1.01
Shattuck Labs entered into an underwriting agreement on June 9, 2026 for a registered public offering of 10.9 million shares of common stock at $4.00 per share, plus 7.9 million pre-funded warrants, with underwriters exercising a full 30-day overallotment option for an additional 2.8 million shares. This is a material dilutive equity issuance that raises capital through the sale of common stock and warrant securities, affecting existing shareholders' ownership percentages and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-11
Item 1.01
Jaguar Health entered into two material equity financing arrangements on June 9, 2026: a $40 million Equity Line of Credit (ELOC) with an accredited investor and a $2 million Preferred Stock Financing with multiple investors including pre-funded warrants. Both transactions involve unregistered or to-be-registered equity issuances that will dilute existing shareholders.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 5.03
The company filed a Series P Certificate of Designation establishing the terms of a new preferred stock class with 8% annual dividends, liquidation preferences, mandatory and optional redemption provisions, and anti-dilution protections. These structural provisions create contingent obligations that could materially affect the company's capital structure and shareholder value.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
Broadcom announced the launch of cash tender offers for certain debt securities on June 11, 2026. While this is a material capital management activity that would affect investor assessment of the company's financial strategy and debt structure, it does not fit neatly into the more specific event categories (it is not a restatement, auditor change, going concern, impairment, delisting risk, bankruptcy, covenant breach, cybersecurity incident, or dilutive equity issuance). Debt tender offers are material refinancing activities but lack a dedicated taxonomy category, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-11
Item 2.03
This Item 2.03 disclosure reports the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Pittsburgh. While the filing explicitly states "consolidated obligations issuance is material to the FHLBank," the disclosure is primarily informational and regulatory in nature—it describes the mechanism and structure of consolidated obligations rather than disclosing a specific new debt issuance event. The prose emphasizes that Schedule A lists obligations "committed to be issued" and notes the FHLBank has not made materiality judgments on particular obligations. This appears to be a standing disclosure of the FHLBank's debt issuance framework rather than a discrete material event triggering Item 2.03, making it best classified as other_material rather than a more specific event type.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-11
Item 3.02
The Company disclosed the sale of 12,690 Class D Common Shares for $350,000 gross proceeds on June 8, 2026, as part of a continuous private placement offering of up to $2.165 billion in common shares under Section 4(a)(2) and Regulation D Rule 506(c). This is a classic unregistered equity issuance that creates dilution to existing shareholders and is material to investors assessing the registrant's capital structure and future equity dilution risk.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-11
Item 5.02
The filing discloses the appointment of Kevin J. Necas, Jr. as Senior Vice President – Chief Accounting Officer and principal accounting officer effective July 2, 2026. While Michael P. Gallagher's retirement is also mentioned, the principal disclosed action centers on the appointment of Necas to a key financial officer role. The appointment of a principal accounting officer is material to investors as it affects the registrant's financial reporting oversight and governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a clear disclosure of shareholder voting results from Airgain's 2026 Annual Meeting held on June 10, 2026. The filing reports final vote tallies for four proposals: election of two Class I directors (Sims and Chung), ratification of Grant Thornton LLP as auditor, advisory approval of named executive officer compensation, and approval of the amended 2016 Incentive Award Plan. All proposals passed. This is a quintessential Item 5.07 shareholder vote results disclosure, material to investors as it confirms governance and compensation decisions.
View raw filing on EDGAR →
8-K
Other material
confidence 55%
filed 2026-06-11
Item 1.01
Badger Meter amended and extended its $150 million revolving credit facility, with a new maturity date of July 8, 2031. The amendment represents a material refinancing and extension of the company's existing credit facilities, affecting its capital structure and liquidity position.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-11
Item 8.01
General Motors Financial Company closed a $1 billion public offering of senior notes due 2031 with net proceeds of approximately $993 million. While this is a material financing event affecting the company's capital structure and liquidity, it does not fit neatly into the standard 8-K taxonomy—it is neither a merger/acquisition (ma_activity), a dilutive equity issuance (dilutive_issuance), nor a debt covenant breach (covenant_breach). The disclosure is a routine debt offering, which is material to investors but lacks the specific event-type indicators that would classify it as earnings_release, going_concern, or other defined categories.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-11
Item 1.01
CarMax Select Receivables Trust 2026-B entered into an Underwriting Agreement on June 9, 2026 for the issuance of approximately $570 million in Asset-backed Notes backed by motor vehicle retail installment sale contracts. This material securitization financing transaction involved the creation and sale of securitized receivables through multiple transaction documents, constituting a significant capital event for the trust.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This Item 5.07 disclosure reports the results of Monte Rosa Therapeutics' 2026 Annual Meeting of Stockholders held on June 11, 2026. The filing presents voting outcomes for two proposals: (1) election of three Class II directors (Andrew Schiff, M.D., Chandra P. Leo, M.D., and Anthony Manning, Ph.D.) with detailed vote tallies (For, Withheld, Broker Non-Votes), and (2) ratification of Deloitte & Touche LLP as independent auditor. This is a textbook shareholder_vote_results disclosure, and the director elections are material to investors as they determine board composition.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a clear disclosure of shareholder voting results from ALX Oncology's Annual Meeting held June 10, 2026, covering three proposals: election of two Class II directors (Daniel Curran, Rekha Hemrajani, and Chris Takimoto), advisory vote on named executive officer compensation, and ratification of KPMG LLP as independent auditor. Item 5.07 explicitly requires disclosure of shareholder vote results, and these outcomes are material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Design Therapeutics' 2026 Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting tallies for two proposals: (1) election of director Simeon George, M.D. as a Class II director with 29,205,208 votes for and 7,608,724 withheld, and (2) ratification of Ernst & Young LLP as independent auditor with 50,077,708 votes for and minimal opposition. These are routine but material shareholder governance matters.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-11
Item 5.07
This Item 5.07 discloses the results of Bolt Biotherapeutics' 2026 annual meeting of stockholders held on June 10, 2026, including voting outcomes for director elections (William P. Quinn and Jakob Dupont, M.D. as Class II directors) and ratification of PricewaterhouseCoopers LLP as independent auditor. The filing presents vote tallies (votes for, against, withheld, abstaining, and broker non-votes) for each proposal, which is the core disclosure required under Item 5.07 for shareholder meeting results.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-06-11
Item 1.01
Gladstone Investment Corporation entered into Amendment No. 13 to its credit facility on June 10, 2026, materially restructuring the debt arrangement by extending the revolving period to June 8, 2029, increasing the facility size from $300 million to $405 million (with ability to reach $500 million), and modifying interest rate terms and covenants. This material modification to the company's capital structure and financing arrangements affects investor assessment of liquidity and leverage.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-11
Item 8.01
Western Digital entered into exchange agreements to swap 1,038,681 shares of SanDisk stock for shares of its own common stock held by institutional investors. This constitutes a material disposition of a significant equity stake (over 1 million shares) in a subsidiary/affiliate, which qualifies as M&A activity under Item 1.01/2.01 framework. The transaction involves a material change in the company's asset composition and shareholder base.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This Item 5.07 filing discloses the final voting results from Heritage Insurance Holdings' annual meeting of stockholders held on June 10, 2026. The section presents results for four proposals: election of six directors, ratification of Plante & Moran as independent auditor, advisory approval of named executive officer compensation, and advisory vote on compensation vote frequency. These are routine shareholder meeting outcomes that materially inform investors about governance and board composition.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-06-11
Item 1.01
Parabilis entered into a Stock Purchase Agreement with Regeneron for a private placement of 4,166,666 shares at $18.00 per share, concurrent with the Company's IPO on June 11, 2026. The unregistered private placement under Section 4(a)(2) and Regulation D includes piggyback registration rights for Regeneron and dilutes existing shareholders' ownership.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Alphatec held its June 10, 2026 Annual Meeting of Stockholders, at which shareholders voted on five proposals: election of seven directors, ratification of Deloitte & Touche LLP as auditor, approval of the 2026 Equity Incentive Plan, approval of the 2026 Employee Stock Purchase Plan, and advisory approval of named executive officer compensation. All proposals passed with substantial majorities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a clear disclosure of shareholder vote results from Cardiff Oncology's Annual Meeting of Stockholders held on June 11, 2026, filed under Item 5.07. The filing presents final voting tallies for four proposals: election of six directors, ratification of BDO USA as independent auditor, approval of an amendment to the 2021 Equity Incentive Plan, and an advisory vote on named executive officer compensation. All proposals passed with substantial majorities, making this a material routine governance disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
This is a clear disclosure of shareholder voting results from an Annual Meeting under Item 5.07. The filing reports final voting tallies for three proposals: election of three directors (Chris Cain, Arlene Morris, and Todd Shegog), ratification of PricewaterhouseCoopers LLP as independent auditor, and an advisory vote on executive compensation. All proposals passed. This is a material event as it confirms the composition of the board and auditor selection, both of which affect investor assessment of governance and financial oversight.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-06-11
Item 5.02
Universal Health Realty Income Trust granted restricted stock awards to four named executive officers on June 10, 2026, with specified share quantities and vesting terms as part of the company's annual long-term incentive compensation program.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-11
Item 5.07
Shareholders of Universal Health Realty Income Trust voted at the June 10, 2026 Annual Meeting on three proposals: election of two Class I trustees (Alan B. Miller and Robert F. McCadden), a nonbinding advisory vote on named executive officer compensation, and ratification of KPMG, LLP as independent auditor.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 99%
filed 2026-06-11
Item 5.07
Alphabet Inc. held its 2026 Annual Meeting of Shareholders on June 5, 2026, with voting results disclosed for fourteen proposals including director elections (Larry Page, Sergey Brin, Sundar Pichai, and others), ratification of Ernst & Young LLP as auditor, approval of stock plan amendments, advisory vote on executive compensation, and multiple shareholder proposals.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-11
Item 1.01
Ciena closed a $2.875 billion private offering of convertible senior notes on June 11, 2026, receiving net proceeds of approximately $2.72 billion. The company used proceeds to repay $1.14 billion of existing debt and repurchase shares, representing a significant capital structure and financing transaction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 93%
filed 2026-06-11
Item 3.02
Ciena sold convertible senior notes and warrants in unregistered transactions under Section 4(a)(2) and Rule 144A, with up to 7,700,978 shares of common stock issuable upon exercise of the warrants. The offering included convertible note hedge and warrant transactions, creating material share dilution.
View raw filing on EDGAR →